Search
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnIt has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Zuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalIt is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … This compound belongs to the thioxanthenes.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.
Synonyms: 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-, N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUOROXylose
go.drugbank.com/drugs/DB09419ApprovedWithdrawnNevertheless, xylose by itself may not necessarily serve many purposes immediately - but its metabolism results in a variety of substrates that can serve important nutritional and biological purposes. … Xylose has also been used as a diagnostic agent to observe malabsorption. Reduction of xylose by catalytic hydrogenation produces the common food additive sweetener substitute xylitol [DB11195].
Aripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigational[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Nb-aripiprazoleLiotrix
go.drugbank.com/drugs/DB01583ApprovedIt consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage.
Categories: Agents used to treat hypothyroidismCalcium polycarbophil
go.drugbank.com/drugs/DB14684ApprovedLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. … is physiologically inert, and does not cause gastrointestinal irritation.
Products: Fiber-ON-tabletGlimepiride
go.drugbank.com/drugs/DB00222ApprovedInvestigationalThe main effect of SUs is thought to be effective when residual pancreatic β-cells are present,[A177715] as they work by stimulating the release of insulin from the pancreatic beta cells and they are also … [A177709] Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization
Products: Co GlimepiridePizotifen
go.drugbank.com/drugs/DB06153ApprovedSandomigran is available in a number of countries but is not approved by the FDA nor EMA. … While it is suggested that pizotifen may act similarly to the classic tricyclic antidepressants [A32538], its full mechanism of antidepressant action is not fully elucidated.
Categories: Analgesics, Non-Narcotic, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome